Pharmaceutical Industry in India Essays

Pharmaceutical Industry in India Essays Pharmaceutical Industry in India Essay Pharmaceutical Industry in India Essay Industry overview Pharmaceutical sector is an important industry of any modern day economic power. Pharmaceutical industry in India has a very humble past. After independence, development of pharmaceutical industry was one of the top agenda of government along with steel and manufacturing industry. The market was protected against competition for a long period of time by giving incentives to small firms, license-raj etc. Today the Indian pharmaceutical industry is the front-runner science-based industries in the country. Today the industry boasts of wide ranging capabilities in the complex field of drug manufacture and technology. The sector is pegged to be worth US$ 7. 3 billion. The annual growth rate is estimated to be around 13%. Reports suggest that the domestic retail market would be worth around US$ 12 billion by 2012. Indian pharmaceutical industry ranks 4th in terms of volume globally and 13th in terms of value. It has 8% share in global sales 20%-24% share in production of generic drugs. The domestic players satisfy almost all of the country’s demand for formulations and bulk drugs. Indian firms aren’t limited to domestic market; they are now competing head on with multi national players in international arena. For many firms, exports constitute 60%-70% of the total revenue earned. Reasons for this strong growth are low cost of manufacturing, low cost of RD, innovative scientific manpower etc. The total pharmaceutical exports in 2007-08 clocked US$ 6. 68 billion against US$ 5. 73 billion in 2006-07 recording a growth rate of 16 per cent. India is poised to be one of the fastest growing pharmaceutical markets in the world. This has led to entry of many major companies in the Indian market and a huge amount of FDI inflow. Evolution of the Indian Pharmaceutical Industry The Indian regulatory system made several arrangements to protect the domestic pharmaceutical industry from foreign competition in its nascent phase. One of them was recognition of only process patents. This built a sound and strong base for strong and competitive domestic market but deterred entry of foreign players. The life of Indian pharmaceutical industry can be broadly divided into two phases, namely Pre-Patent regime and Post-Patent regime respectively. Lets take a look at both of them in detail: Pre-Patent Regime: This period can be segmented into various time periods for better understanding: 1947-1970 During this period country was trying to stand on its feet after gaining independence. The pharmaceutical industry had to be built from scratch. Though several domestic players had sprung up in market but their impact on market was limited. The reason was their inability to compete with MNC players who had better access to resources, better technical know how and access to larger amount of funds. These foreign players imported formulations and sold them in India. They were neither contributing to pharmaceutical industries nor to the manufacturing industries in India. People had low spending and restricted access to healthcare facilities because of low levels of income. The government had realized that dependence on imported drugs had to be reduced so that essential drugs could be made available to public at cheap prices. For this country needed to build indigenous drug production capabilities. To fulfill this objective Hindustan Antibiotics Limited (HAL) and Indian Drugs Pharmaceutical Limited (IDPL) were setup in 1954 and 1961 respectively. These companies soon established themselves as major producers of critical drugs, which, were being imported at that time. 1970-1979 The MNCs continued to dominate the domestic market in spite of steps taken by government. Government introduced two legislations in 1970 to accelerate the process of self-reliance and indigenization. These were Indian Patent Act and Drug Price Control Order (DPCO). These two regulations provided the launch pad for the Indian pharmaceutical industry to take off into a new growth spiral. Indian Patent Act: The act granted patents only for methods and processes used to manufacture the substance. This allowed the domestic players to reverse engineer the drugs present in market and find its constituents. They started making the product using the same bulk drug by using a modified production process. Drug Price Control Order: Government regulated prices of 354 essential bulk drugs and formulations to ensure wide spread availability of drugs at a reasonable price. These two legislations changed the industry structure and growth pattern. Several small-scale ndustries (SSI) came into existence in formulation business. They had significant advantage as their products were out of purview of price control. Low entry barriers, abundance of bulk drugs and dispersed market acted as additional catalysts. All these factors had a significant impact on the position of MNCs in India. These regulations introduced the concept of price control did not recognize product patents. Therefor e the MNCs had no incentive of introducing new drugs in the market. Their overall share in formulations started to decline as time progressed. 1979-1987 Government in 1979 amended DPCO. Number of drugs under purview of DPCO was bought down from 354 to 163. Government also increased the permissible mark-up on drugs from 40%-60% to 75%-100%. DPCO also regulated the production by fixing ratio between formulation and key bulk drugs. This ensured continuous and uninterrupted supply of key bulk drugs. Investments made by government in past had started bearing fruit. IDPL and HAL provided technical assistance to smaller players in establishing their foothold. Hence even smaller players started to supply critical drugs to market. Indian firms started to invest in RD because of availability of skilled researchers in country. This resulted in launch of new drugs through process re-engineering. Government funded Central Drug Research Institute (CDRI) and Council of Scientific and Industrial Research (CSIR) made major contribution to the research base. Indian firms had advantage of low cost structure and very good reverse engineering technical skills. After they had established themselves in domestic market they turned their attention towards export. They took measures to utilize their advantage in global arena and were quite successful. There was no improvement in conditions of MNC’s. High tariffs caused the prices of their product to go up. Price control measures taken by government directed them to sell at cheaper price. Therefore they focused on specific sectors where they still had a stronghold. They were reluctant to launch new products in country because of lack of proper patent protection. This resulted in overall decline of their market share. 1987-1994 This was a consolidation period of the industry. The entire industry registered a double-digit growth rate through the period. This high growth rate was attributed to rise in per-capita income of people and introduction of new drugs at cheap price. The increase wasn’t limited to domestic market. While bulk drug production grew at CAGR of 16%, bulk drug export grew at CAGR of 40%. By 1994 exports comprised 50% of total bulk drug production. To meet the ever-increasing demand, companies had to invest heavily in increasing their capacities. High growth rate also attracted new players to the market. Competition in market increased manifold as the number of players in the market doubled over this period. Most important development of this period was liberalization program initiated by the government. The tariff barriers were lowered which leveled the playing field for MNCs vis-a-vis domestic players. This also increased foreign investment in domestic pharmaceutical industry. The liberalization policy also benefited domestic players who made efforts to increase their global presence due to lower tariff and non-tariff barriers. 1995-2001 The major development of this phase was government’s commitment to recognize product patent regime after 2005. This increased the expectation of MNCs. Most of them increased their equity stakes in Indian operations. MNCs also realized that they could convert India into their manufacturing base. India had quality manufacturing facilities at cheap costs. Domestic firms too had saturated Indian market. They were focusing on global markets more seriously now. They entered into alliances with MNCs, entered into JV’s in overseas market, set up world-class manufacturing facilities and strengthened their brands to strengthen their position. The small players finally came of age and gave serious competition to their bigger counterparts. Even though market grew at 15% intense competition from smaller players pushed the bigger players towards generic formulations. Bulk drugs had lower margins because of intense competition. To overcome this most players forward-integrated into formulation manufacturing or increased their export to non-regulated markets where margins were higher. 2001-2004 During this period domestic players increased their focus on market of generic drugs. They invested in RD and upgraded their manufacturing facilities to comply with GMP norms. During this period the domestic formulations market registered a decline, barring a few segments. MNCs were strengthening their interest in domestic market as product patent regime was to be implemented in 2005. Post-Patent Regime 2005-2006 Government passed an ordinance in 2005 implementing the product-patent regime. This move was aimed at bringing India at par with global pharmaceutical market. Other major developments during this period were implementation of VAT, shift in excise duty levy to MRP based levy and implementation of good manufacturing processes. During this period Indian players established themselves in global market with their innovatively engineered generic drugs API. 2006-2007 The new pharmaceutical policy has been center of attraction. Government wanted to bring essential drugs on which the manufacturers made fat profits under the purview of DPCO. The proposed pharmaceutical policy was aimed at bringing 354 essential drugs under purview of DPCO so that they are within reach of common man. The policy has provision of limiting MAPE to 150% to put a cap on profits earned by pharmaceutical firms. The duties on API were reduced to encourage manufacturing. Government has also set up NPPA to regulate pricing of drugs in India. Companies will have to sell their drugs at price decided by NPPA. Regulatory Environments in various parts of the world Europe The European Medicines Agency (EMEA) is the apex body, which governs medicine industry in Europe. Scientific opinions of the agency are prepared by committees i. e. the committee for medicinal products for human use (CHMP), the committee for medicinal products for veterinary use (CVMP), the committee for orphan medicinal products for rare diseases (COMP) and the new committee on herbal medicinal products (HMPC). EMEA performs the scientific evaluation of the quality, safety and efficacy of medicinal products in EU. EMEA also coordinates the resources for scientific evaluation and assessment regarding products undergoing the mutual recognition procedure and the master files for plasma and vaccine antigens. EMEA also provides guidance for companies requesting scientific advice. It also provides scientific advice before the application of new marketing authorization for centralized and mutual recognition procedures. Scientific Advice Working Party (SAWP) does this task. In order to sell products in EU markets firm have to obtain a license. This license is granted by CHMP after it assesses the product in question. European Pharmacopoeia (Ph Eur) specifies the quality specifications for pharmaceutical preparations and their ingredients. Before submitting a Marketing Authorization Application (MAA) the firm is required to show the safety and efficacy of the medicinal product. To show this local clinical data should be generated for a new medicinal product. Thus it is necessary to conduct clinical trails before launching a product in EU. If the product has already proved safety and efficacy in some other country then a bridging clinical study is sufficient. The initial license granted to a firm has to be renewed after five years. The risk-benefit balance is revaluated. If the result of re-evaluation is positive then the firm is granted the license for unlimited period of time unless the competent authority decides otherwise. In cases of drugs that require long-term safety study, the license for unlimited period is usually granted after 2-3 re-evaluations. The EU pharmaceutical legislation is very extensive and robust. In order to ensure high quality and safe therapies it provides extensive rules and guidance on licensing procedures for medicinal products. USA Pharmaceutical sector in USA is regulated by the department of Health and Human Services. The apex regulatory body is US FDA, which enforces the basic drug and food legislations. When a drug manufacturer develops a new drug, first the drug is tested on animals. Then he obtains approval for human trials through Investigational New Drug (IND). The data collected through human clinical trials in IND and animal studies is used to file a New Drug Application (NDA). NDA is used to communicate to FDA about safety and effectiveness of the drug, high quality manufacturing standard for the drug and appropriate labeling of the drug. New drugs are developed under patent protection. This grants exclusive marketing rights to the developer of the drug. After expiry of the patent period, other firms can sell a copy of the drug. This copied version of drug is called as generic drug. In order to get approval from FDA to sell generic drugs, firms must file for an Abbreviated New Drug Application (ANDA). Generic drug sector became very lucrative because the manufacturers of generic drugs didn’t have to invest in costly animal studies and human clinical trials. Also the pharmacists were given the right to sell substitute generic drugs instead of a specific drug unless explicitly specified by the doctor. To get an FDA approval for their ANDA the firms had to ensure that their drugs contains the same amount of active ingredient as the original drug, it should be identical in dosage form, strength and administration method and manufactured under the same manufacturing standards as for the original drug. A Drug Master File (DMF) is submitted to FDA that contains almost all information related o the drug. Some information in the file may be of confidential nature. India In India both the central government and the state government share the responsibility of regulating the pharmaceutical industry. The Drug and Cosmetic Act and Drug and Cosmetic Rule are the legislations passed by the government in this regard. Through this legislation the government regulates import, manufacture, sale and distribution of drugs in India. The central government plays as the coordinator of policies like drug approval, clinical trials, setting up standards, controlling the quality of imported drugs etc where as the state governments see that the policies laid down by the central government are being implemented by the firms. The Drug Controller General of India (DCGI) co-ordinates all the activities involved. Pharmaceutical industry in India regulated on basis of price, patent quality. DPCO fixes an upper limit on critical formulations API. NPPA regulates the pricing of all the drugs manufactured or sold in India. A firm cannot price its drug on its own; it has to be approved by NPPA. NPPA has also put an upper limit of 150% on MAPE. If the firm invests heavily in RD then the limit is increased by 50%. In 1995 government had amended DPCO to limit the size of drugs under purview of DPCO to 74. After implementation of product patent regime government is mulling over bringing the number of drugs under DPCO to around 200. The Drug Cosmetic act specifies the quality standards to be met for any drugs that is manufactured, sold or distributed in India. Manufactures have to follow GMP in their manufacturing plants. FDI up to 74% is allowed on the automatic route in the case of bulk drugs, their intermediate Pharmaceuticals and formulations (except those produced by the use of recombinant DNA technology). The Government considers FDI above 74% for manufacture of bulk drugs on a case-by-case basis. It’s allowed only for manufacture of bulk drugs from basic stages and their intermediates. It also extends to bulk drugs produced by the use of recombinant DNA technology and the specific cell/tissue targeted formulations if it includes manufacturing from basic stage. Government had liberalization plans of increasing the FDI cap to 100% and making the process of investing more easily and investor friendly. The plans were not implemented because of political pressure exerted by the Left Parties on the government. Recent Developments Raw material shortage hits pharmaceutical firms Olympic games in China have put brakes on high-flying Indian pharmaceutical industry. In order to present its clean image before the world during the games, China has ordered to close various drug manufacturing units to prevent environmental degradation. This has caused a scarcity of raw material in India and has pushed up prices of generic medicines. Daiichi Sankyo buys majority stake in Ranbaxy Daiichi Sankyo Company, Ltd (Daiichi Sankyo) has bought majority stake in Ranbaxy Laboratories Limited (Ranbaxy) from the Singh family, the largest controlling shareholders of Ranbaxy. The deal is subject to regulatory approvals. This deal will allow Ranbaxy access to global markets that have been off-radar for the firm till now. Daiichi Sankyo is looking forward to gain a stronger foothold in a very fast developing Indian market as well as the base established by Ranbaxy in USA. Sun Pharmaceuticals gets USFDA nod for generic Depakote The USFDA has granted a final approval to Sun Pharmaceutical Industries Ltd for its Abbreviated New Drug Application (ANDA) for generic Depakote, divalproex sodium delayed release tablets. Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures. US Congress to probe FDA`s Ranbaxy case The US House Energy Commerce committee is investigating the FDAs stance on the Ranbaxy case. The committee is to probe FDAs handling on Ranbaxys imports. The committee will also probe whether FDA knowingly let unsafe medicine to enter US. Sun Pharmaceuticals Taro deal Sun Pharmaceuticals, offered $454 million, all in cash, to buy out an Israeli generics manufacturer, Taro Pharmaceuticals. The deal has not been completed as yet because of encountering several roadblocks. Taro Pharmaceuticals is an Israeli pharmaceutical firm with a global presence. By acquiring Taro, Sun is trying to enter the low-competition, specialized segments like dermatology and pediatrics. Taro’s large presence in the Canadian market is also an attraction for Sun. Key Features of quarter April-June FY09 Improvement in product and geographic mix: Higher contribution from exports (62%) for generics and higher proportion of CRAMS business (46%) were the key highlights of the quarter. Improvement in margins: led by higher overseas and CRAMS sales, a 5. 9% YoY depreciation in the Rupee v/s the USD and increased captive consumption from companies like Dishman, Lupin and Piramal Healthcare. Raw material pressure to persist in the near term: China’s decision to (i) shut down polluting plants around Beijing and (ii) restrict the movement of hazardous chemicals in view of the Olympics resulted in raw material shortages and a consequent increase in prices. A rise in crude oil prices resulted in increases in the price of API solvents and intermediates. Our interaction with a few companies suggests that raw material shortage may persist for the next one-two quarters. Depreciating rupee leads to MTM losses on Forex debt: A 7. % and 9% QoQ depreciation of the rupee v/s the USD and Euro respectively resulted in most companies declaring MTM losses on their FCCBs and foreign debt. Prominent among the losers were Ranbaxy, Jubilant and Cipla. GSK recently signed a deal with Aspen and Strides GSK Pharmaceutical has collaborated with Aspen through which it would have access to a portfolio comprising 1200 products and 450 molecules of Aspen and its JV with Strides. GSK would get these products approved in 95 emerging markets and distribute and market these as well, while Aspen will continue to market in Sub-Saharan Africa and other countries. Jubilant signs drug discovery pact with Amgen Jubilant Bosys Ltd. and Amgen Inc. , the largest US-based biotech company on Monday announced a drug discovery partnership. As per the deal, Amgen and Jubilant will collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas. Jubilant will develop early preclinical candidates emanating from Amgens early discovery efforts for an initial term of three years. Amgen will have responsibility for the subsequent pre-clinical and clinical development and commercialization. Amgen will retain / own the drugs developed under the collaboration with worldwide commercialization rights. Jubilant Biosys will partner in early-preclinical development effort from its state of the art Jubilant Research Centre Bangalore, while Amgen will pursue later stage pre-clinical and clinical development and commercialization of the drugs in global markets. The financial terms include a combination of research funding and success-based milestones paid to Jubilant during pre-clinical and clinical development for multiple projects undertaken by the collaboration. The total financial Milestone value is subject to successful development and commercialization of the portfolio of novel drugs. Glenmark`s molecule for Neuropathetic Pain to enter Phase I trials Glenmark Pharmaceuticals Ltd has announced that its candidate for Neuropathic Pain, Osteoarthritis and other Inflammatory Pain-GRC 10693 is entering Phase I trials. The company intends to develop GRC 10693, a cannabinoid-2 (CB-2) receptor agonist, in neuropathic pain as the primary indication. The molecule has been filed for Phase-I approval with European regulatory authorities. Biocon, Abraxis launches ABRAXANE in India Biocon Limited and Abraxis BioScience, Inc, a fully integrated biotechnology company announced the launch of ABRAXANE (paclitaxel protein bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy, ABRAXANE is now available in India as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). The Phase III clinical trial in the U. S. demonstrated that ABRAXANE nearly doubled the response rate, significantly prolonged time to progression, and significantly improved overall survival in the secon line setting versus solvent based Taxol in the approved indication. The Medical House ties up with Dr Reddys Labs The Medical House Plc, a drug delivery specialist has signed a non-exclusive development, licensing and supply agreement with Dr Reddys Laboratories. The agreement covers an initial five-year term of supply, within US, European Union and Canada, with an option for Dr Reddys to extend the agreement to the rest of the world, on mutually agreed terms, the company said in a filing to the London Stock Exchange. The duration of the agreement can also be extended by mutual agreement and the development costs associated with customization would be paid to The Medical House (TMH) in addition to reimbursement of all agreed external costs. Strides completes acquisition of Ascent Pharmahealth Strides Arcolab has completed the acquisition of controlling interest in Ascent Pharmahealth Limited (formerly Genepharm Australasia Limited), thereby making Strides the 4th largest Generics Company in Australia. Strides now holds 50. 1% stake in Ascent Pharmahealth Limited, an ASX listed company. At final closing in Sept ’08, Strides may own upto 55% in Ascent Pharmahealth Ltd. Shareholders have voted to change the name of Genepharm Australasia Limited to Ascent Pharmahealth Limited. Ascent Pharmahealth Limited will include the assets of Drug Houses of Australia [DHA] in Singapore, a wholly owned subsidiary of Strides Revenue in excess of US$90mn on a combined Performa basis. Lupin acquires Hormosan Pharma Lupin Ltd has acquired Hormosan Pharma GmbH (Hormosan), a German Sales and Marketing generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS). Hormosan, with total sales of Euro 6. 8mn for the year ended December 2007, develops, licenses and markets a range of generics in Germany. Hormosan has a complementary product portfolio with products in the Central Nervous System and Cardiovascular therapeutic segments. Hormosan has created a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector. Besides strong key account management the company also has a successful in Regulatory team, Pharmacovigilance, Medical Information and Marketing teams. Aurobindo Pharma receives nod for 2 ANDAs Aurobindo Pharma has received final approval from the US Food Drug Administration (USFDA) for 2 ANDAs namely Ceftriaxone for injection USP 250mg, 500mg, 2g and Ceftriaxone for injection USP 10g pharmacy bulk pack. These are Cephalosporins under the Anti-infective segment. Lupin Pharma receives nod for Divaiproex. Sodium Tablets Lupin Pharmaceuticals, Inc. (LPI) has received final approval for the Companys Abbreviated New Drug Application (ANDA) for Divaiproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U. S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced. Lupin Divaiproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories Depakote tablets. Depakote had annual sales of approximately US$ 803mn for the twelve months ended March 2008, based on IMS Health sales data. Dr Reddy`s lab to invest in Perlecan Pharma Dr Reddys lab has purchased holding of Citigroup Venture Capital International Mauritius Limited its nominees and IDBI Trusteeship Services Limited (the merged entity after its merger with The Western India Trustee and the Executor Company Limited) in Perlecan Pharma Private Limited. The Board of Directors of Dr Reddys Laboratories Limited at their meeting held on July 21, 2008 had approved this proposal aggregating to US$18mn. References: pharmaceutical-drug-manufacturers. com/pharmaceutical-industry/ thehindubusinessline. com/iw/2004/07/25/stories/2004072500401000. htm ibef. org/industry/pharmaceuticals. aspx www. indiainbusiness. nic. in/industry-infrastructure/industrial-sectors/drug-pharma. htm

Social Networking Essay Example | Topics and Well Written Essays - 500 words - 1

Social Networking - Essay Example Individuals of all ages indulge in the activities and attractions offered by such websites. Social networking websites have a very vast effect on the individual using it. I have been using social networking websites since the last four years. Social networking has both positive and negative effects on the education, personal development, interpersonal skills, relationships and psychological aspects of the individual. Social networking web has emerged as a remarkably significant form of communication and socializing amongst the youth. Some utilize the social networking for playing their favorite online games, while others use it for communicating with their friends through pictures, videos and chatting. Human relations are another aspect that is affected by the social networking usage. This aspect has its own flaws and positive points that can affect the individual using the websites. Human beings always show a deep interest in the nature and personalities of their friends and peers. They are curious about their activities, pastimes, current incidents, feelings and opinions. People are always in an effort to â€Å"know more† about the people around them and intrude in their private information. Social networking web has given an opportunity to the users to display their personal information, feelings and life events on the internet. Thus, they also get an equal chance of viewing and interfering in other people’s information as well.

United States Economy Research Paper Example | Topics and Well Written Essays - 1500 words

United States Economy - Research Paper Example Introduction: History of the economy of United States We are going to go aboard on a journey to look at the economy of United States. This inquisitiveness will lead us to scrutinize the economy’s operations, structures, and performance at a given time and its changes over time. We are going to look at the industries that have become additionally important in the United State economy and how the government is taking over the share of the nation’s output. The growth of people’s income, the distribution of people’s income among many more will be addressed. For a long time, the key to United States economy had been southern agriculture. But the civil war which began in April 1861 nearly destroyed everything. However, the country came out of the war with economic tools to put up the strongest economy in the world. Within 30 years, the United States led the whole world in manufacturing. After 80 years, it contained half of the world’s industry. From 1871 to 1890, United States experienced the second industrial revolution. These are social and economic changes that result from wide use of machines in production. Inventions made work easier and safer and this created the whole industry. Factories started operating using mass production and all this led to growth of the economy. Between 1861 and 1941, the economy of United States had risen from boom to bust. This was a period between the civil war and II world war. In the foremost or subsequent decade, the United States economic market growth took place in an environment where policies set by regulators were dramatically changing and conditions in the market were unstable (Garcia, 2011). This... For a long time, the key to United States economy had been southern agriculture. But the civil war which began in April 1861 nearly destroyed everything. However, the country came out of the war with economic tools to put up the strongest economy in the world. Within 30 years, the United States led the whole world in manufacturing. After 80 years, it contained half of the world’s industry. From 1871 to 1890, United States experienced the second industrial revolution. These are social and economic changes that result from wide use of machines in production. Inventions made work easier and safer and this created the whole industry. Factories started operating using mass production and all this led to growth of the economy. Between 1861 and 1941, the economy of United States had risen from boom to bust. This was a period between the civil war and II world war. In the foremost or subsequent decade, the United States economic market growth took place in an environment where policies set by regulators were dramatically changing and conditions in the market were unstable (Garcia, 2011). This resulted to disappointing and volatile profitability of financial sector. Financial sector recorded 1.5 percent of Gross Domestic Product from 1960 to 1970s but after wards reduced to 1 percent in 1980s. In 1990s, the Gross Domestic Product began to rise and within ten years, it was up to 3 percent.

Gender Differences in Communication

Gender Differences in Communication   The Difference of Language Used Between Men and Woman Many have wondered why men and women are so different. Everyone knows that both genders have a different way of talking to each other but no one knows exactly why. Why do males speak differently around females than they do with themselves? Is it through gender stereotypes that cause different language features they use in their speech? Or is there an an outside influence that is causing this phenomenon? The different speaking styles males and females use to converse, shows that their conversations are limited because of the influences of society. Throughout time, males were seen to have a different style of communication with females compared to their usual conversations with their fellow sex. This could also be said for females in vice versa. In male to male conversations, men are more seen to tease and joke around with their friends through profanity, sarcasm, or humor. In addition, they tend to avoid serious and emotional topics while females have these type of topics as their every day conversations. In female to female conversations, women are more careful about the choice of words they use and reflect upon the topics of their conversations. But why do men tend do avoid emotional/serious topics and why do females have to think before they speak? Can men also talk to women as if they were talking to their fellow sex? A sample of fifty California State University of Fullerton students were observed and ask about their opinions of this matter. Forty out of fifty males have responded that revealing their feelings, private li ves, or relationships would show their weaknesses and that it would lower their status as a confident, strong male. Forty-six out of the fifty females have also stated women are more cautious about their choice of words because females tend to be more sensitive and judgmental. And when the males were asked if they can talk to females the same way they talk to their friends, most of them said they cant. They have stated that their words or jokes could be too harsh and possibly hurt a girls feeling as females tend to be more sensitive or emotional. After the experiment, it was concluded that gender stereotypes was a possible major influence in the reason why men and women both speak differently. Although it is concluded that gender stereotypes is an influence on how men and women speak, how early is one introduced and influenced to gender stereotypes? Parents are the role models for their children. Their point of view and beliefs can also influence their childrens beliefs and views. For example, a Dad will tell his son not to cry because men dont cry over trivial things or a Dad will tell his daughter that she is his princess and treats her very gently. A mom can also tell her son to never hit a girl or to never say any mean things to a girl. Therefore, the male would never speak harshly towards or girl or show weakness. Another example would be a Mom telling her daughter her words have consequences and to always be kind to others. Therefore, the female would speak in a polite matter and is cautious with her words. It is shown that the parents can unintentionally integrate the concepts of gender stereotypes in their mind to help their child fit into the social norms of what is right and what is wrong. However, how early can a child learn to differentiate their language between both genders? A study of a one day observation on fifteen preschoolers have been performed. In result, all fifteen pre-schoolers have equally treated their classmates the same. The boys would talk just as roughly to the girls as they would to the boys and the girls would also join in yelling some insults when provoked. However, in recess a boy and girl got injured while running around the slide. The teacher hold the crying girl and comforted her while the teacher aide who took care of the boy, discouraged him from crying. One can see that the children in this early age of development are still oblivious to differentiation of language in genders. Though as they grow up, their personal experience with the people they interact and the people who influence them would slowly change how they speak towards others. Men and women have different perspectives on the world of communication. Women use the language as an act of sharing and an opportunity to increase intimacy with others, as well as to   express themselves and seek advice from others. While men often more focused on small talk that often revolves around topics related to business, sports, weather, and news where they have a clear purpose of the conversation in mind. (World of Psychology, 3) There are many different types of perspective seen by both genders. But can gender change their fixed mindset to a growing mindset? What would happen if males and females were to change their perspective of language and be more tolerant towards each other? For example, would it be possible for girls to be more tolerant of what others says or for males to be more expressive in their conversations? A population of ten Fullerton College students were asked. Eight out of ten said that it would not be possible because gender stereotypes have been ingrained into our culture. Therefore, the majority of the people will always have a fix mindset about the language we use towards different genders. In spite of that, two of the ten have stated that it could be possible but it would   gradually take over a long period of time. It is evident that men and womens style of language and communication differs in many ways. The analysis of the studies performed for this research shows that the differentiation of the language between genders is due to gender stereotypes. As well as it could be also due to the fact how the person was raised and what types of people he or she was surrounded with. Although both genders speak the same language, the choice of words have been limited because of the pressures of the societys norms. However, there is hope that someday the people will adapt into a growth mindset and erase the language barrier between males and females. Works Cited 6 Ways Men Women Communicate Differently. World of Psychology. N.p., 16 July 2014.  Web. 13 Feb. 2017.

Grant, Hero of A Lesson Before Dying Essay

How we act or react in difficult situations defines our persona. Sometimes these situations provide opportunities to be a hero. After reading Grant Wiggins’s own definition of a hero, it is apparent that Grant becomes a hero. Grant states, â€Å"A hero is someone who does something for other people. He does something that other men don’t and cant to. He is different from other men. He is above other men. No matter who those other men are, the hero, no matter who he is, is above them.† Grant becomes a hero by earning an education to become a teacher, undergoing psychological changes, and counseling Jefferson to die with dignity. A hero is different from others and does something others cannot. Grant’s drive to defy stereo type, become a teacher, and contribute to the community demonstrates that he is a hero. Grant is an African American son of cane-cutters who worked on a Louisiana plantation. He grew up working a labor job and was expected by society to continue as a laborer. Through determination he was able to escape his surroundings to earn a college education. He returns as an educated university man hoping to make a positive impact on society, but is still looked down upon. College gave him a new perspective and educated way of speaking and thinking, but he was still not equal to the whites. Grant continued to persevere through segregation and unfair treatment. He maintained his goal of making a difference by teaching in a church without desks or other supplies. Grants ability to escape his environment and stereotyping, earn an education, and return to his community to make changes, makes him different from others in his community. Grant was different from others and taught in conditions that most could not. Grant is a hero. Grant proved himself a hero, not only by overcoming struggles with racism, but with overcoming struggles within his own mind. A hero is above all other men. Many times a change must take place for man to become a hero above all other men. Throughout the novel, Grant undergoes psychological changes that allow him to become a hero. Grant’s life is filled with rage for the way he is treated by whites. Eventually this rage becomes self-loathing and cynicism, because he feels he is taking the unjust treatment from whites lying down. This downward spiral causes him to alienate himself from people he loves and feel that the community is helpless. During a conversation with Vivian, Grant says, he cannot face Jefferson because he cannot face himself and his own life. Vivian helps Grant realize that he has left the South in the past, has returned, and still has not left. This helps him realize that he is there for a reason. Another change happens when he accepts the task of helping Jefferson. At first Grant is angry and believes that Miss Emma wants him to perform a difficult and maybe impossible task of convincing Jefferson to die with defiance and character. After accepting this task and dealings with Jefferson, Grant realizes what a hero is and he can have an impact on the community. Finally when Grant breaks down in front of his students he realizes that he is ready to connect with the children that he has been so strict with. Many heroes have to overcome an inner struggle to realize their potential for greatness. Eventually through his interactions with his family, Vivian, Jefferson, and students he realizes to view everyone positively which gives him the strength and courage to make an impact in his community. Grant’s actions with Jefferson embody the heroic effort of doing something for someone else. Jefferson is thought of as an animal, and even compared to a â€Å"hog†. Grant wants Jefferson to believe that he is more than convict and just a black man. Grant wants Jefferson to believe that he can change society. Grant visits Jefferson regularly, councils him, gives him a radio, and hope. Before Jefferson’s death, Grant confides in him and says, â€Å"My faith is in you, Jefferson.† Through his efforts and faith, Jefferson completes his transformation into a dignified human being. Grant’s perspectives change throughout the novel as a result of his interactions with his family, Vivian, Jefferson, and his students. When given the opportunity to be a hero, he accepts and becomes a hero. His escaping his environment and stereotyping to become a teacher, overcoming psychological struggles, and helping Jefferson die with dignity proves that he is a hero in the novel.

 Business Law Case

Brown is a farmer who, amongst other activities, has been in the business of raising chickens on large scale. The baby chicks require a continuous supply of a oxygen to survive and the necessary equipment for that purpose is connected to the electric power supplies to the farm. In thee past brown had suffered a minor loss of chickens from an interruption in this electric service and had, as a result, installed an auxiliary battery operated power generator in the barn to be available as an emergency back-up. He had taken further precaution of having a battery-operated power failure detector in his bedroom so that if the electrical power in the farmhouse failed, a warning signal would alert him to the potential danger of loss of electricity to his operation.ElectriChauncey is a driver for Gardiner transport ltd. While driving the company’s truck on a night run, Chauncey allowed the vehicle to wander onto the shoulder of the road where the upper part struck overhead wires. As a r esult, electric power service in the areas was interrupted for a periods of five hours. The interruption extinguished the supply of oxygen to browns’ barn and some 30,000 chickens died. Unfortunately, brown had temporarily disconnected the alarm detector in his bedroom and so on the one occasion when he needed it, it was not in operation. Brown bought an action for damages against both Chauncey and Gardiner transport ltd, to compensate him fir the loss of his chickens.Discuss the merits of the plaintiff’s (plaintiff) case? What will be the de fences?

Section 1 Typically, we need a well-balanced meal to give...

Section 1: Typically, we need a well-balanced meal to give us the energy to do day-to-day tasks and sometimes we aren’t able to get home cooked meals that are healthy and nutritious on a daily basis, due to the reasons of perhaps low income or your mom not being able to have the time to cook. People rely on fast food, because it’s quicker and always very convenient for full-time workers or anyone in general who just want a quick meal. Eric Schlosser, author of Fast Food Nation argues that Americans should change their nutritional behaviors. In his book, Schlosser inspects the social and economic penalties of the processes of one specific section of the American food system: the fast food industry. Schlosser details the stages of the fast†¦show more content†¦He recounts the agony of dozens of people who have died of infected meat, describes the sufferings of the illegal slaughterhouse workers, and details the sad fate of the independent business owners. In thi s effort, he counts the successes of the people against the corporations. Schlosser aims his book at the average consumer; he urges them to simply stop buying it. He is able to persuade the reader to join him in his accusation of the fast food industry with the revolting details he presents. Although never directly stated, the book is filled with the idea that you, too, will eventually pay the real price of fast food. Even though the truth comes out about fast food, people often disregard the consequences of it, they still eat fast food due to the cheap price and the tastiness of it, which is simply just flavoring less than 2 percent of beef. Section 2: Eric Schlosser argues that the slaughterhouses and meatpacking industries are unsafe, unhygienic and employees are treated falsely. The industry has made and will not make any effort to change its environment and habits. The companies are afraid to make changes to the industry because slowing the pace to protect workers can lead to a competitive disadvantage. Meatpacking is now the most dangerous job in the United States and the industry consists mostly of illegal immigrants and unskilled workers such as teenagers. The conditions are unsafe and unsanitary and they are rarely paid attention to.Show MoreRelatedA Short Note On The, Inc.1838 Words   |  8 Pageshad an impact in the markets. First, the telecommunication market has dropped 7% in 2002 following WorldCom scandal. It was easy to see that WorldCom scandal on the global market. Second, the scandal caused HGK’s debt security. HGK, standing for Harris, Greenhouse, Kutzel HGK Asset Management company in New Je rsey, invested in $130 million in WorldCom and lost them all, which hurt their growth a lot. Third, WorldCom scandal depreciated the value of dollars. Foreign investors’s confidence in the USRead MoreAudit and Wall Street13173 Words   |  53 Pagesfund in the U.S. It invested the assets of the New York state and local employees‟ retirement system and of the New York State and Local Police and Fire retirement system. The pension fund lost over $300 million of its investments in WorldCom. The HGK Asset Management, a registered investment advisor, also purchased about $130 million of the debt securities offered by WorldCom on behalf of union sponsored pension and benefit plan and lost it all (in re WorldCom, inc., 2003). Institutional investors